RhumbLine Advisers’s Unity Biotechnology UBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-129
| Closed | -$174 | – | 4332 |
|
|
2024
Q2 | $174 | Hold |
129
| – | – | ﹤0.01% | 4324 |
|
|
2024
Q1 | $211 | Hold |
129
| – | – | ﹤0.01% | 4215 |
|
|
2023
Q4 | $248 | Hold |
129
| – | – | ﹤0.01% | 4228 |
|
|
2023
Q3 | $309 | Hold |
129
| – | – | ﹤0.01% | 4253 |
|
|
2023
Q2 | $328 | Buy |
+129
| New | +$328 | ﹤0.01% | 4333 |
|
|
2021
Q2 | – | Sell |
-3,736
| Closed | -$224K | – | 3104 |
|
|
2021
Q1 | $224K | Sell |
3,736
-155
| -4% | -$9.29K | ﹤0.01% | 2802 |
|
|
2020
Q4 | $204K | Buy |
3,891
+260
| +7% | +$13.6K | ﹤0.01% | 2830 |
|
|
2020
Q3 | $126K | Sell |
3,631
-450
| -11% | -$15.6K | ﹤0.01% | 2825 |
|
|
2020
Q2 | $354K | Buy |
4,081
+417
| +11% | +$36.2K | ﹤0.01% | 2494 |
|
|
2020
Q1 | $213K | Buy |
3,664
+10
| +0.3% | +$581 | ﹤0.01% | 2553 |
|
|
2019
Q4 | $263K | Buy |
3,654
+44
| +1% | +$3.17K | ﹤0.01% | 2654 |
|
|
2019
Q3 | $220K | Buy |
3,610
+92
| +3% | +$5.61K | ﹤0.01% | 2717 |
|
|
2019
Q2 | $334K | Buy |
3,518
+399
| +13% | +$37.9K | ﹤0.01% | 2560 |
|
|
2019
Q1 | $253K | Buy |
3,119
+82
| +3% | +$6.65K | ﹤0.01% | 2631 |
|
|
2018
Q4 | $494K | Buy |
+3,037
| New | +$494K | ﹤0.01% | 2304 |
|